<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35970935</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0447</ISSN><JournalIssue CitedMedium="Internet"><Volume>93</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Pediatric research</Title><ISOAbbreviation>Pediatr Res</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2 infection in children and implications for vaccination.</ArticleTitle><Pagination><StartPage>1177</StartPage><EndPage>1187</EndPage><MedlinePgn>1177-1187</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41390-022-02254-x</ELocationID><Abstract><AbstractText>The COVID-19 pandemic caused by novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for more than 500 million cases worldwide as of April 2022. Initial estimates in 2020 found that children were less likely to become infected with SARS-CoV-2 and more likely to be asymptomatic or display mild COVID-19 symptoms. Our early understanding of COVID-19 transmission and disease in children led to a range of public health measures including school closures that have indirectly impacted child health and wellbeing. The emergence of variants of concern (particularly Delta and Omicron) has raised new issues about transmissibility in children, as preliminary data suggest that children may be at increased risk of infection, especially if unvaccinated. Global national prevalence data show that SARS-CoV-2 infection in children and adolescents is rising due to COVID-19 vaccination among adults and increased circulation of Delta and Omicron variants. To mitigate this, childhood immunisation programmes are being implemented globally to prevent direct and indirect consequences of COVID-19 including severe complications (e.g., MIS-C), debilitating long-COVID symptoms, and the indirect impacts of prolonged community and school closures on childhood education, social and behavioural development and mental health. This review explores the current state of knowledge on COVID-19 in children including COVID-19 vaccination strategies. IMPACT: Provides an up-to-date account of SARS-CoV-2 infections in children. Discusses the direct and indirect effects of COVID-19 in children. Provides the latest information on the current state of global COVID-19 vaccination in children.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nathanielsz</LastName><ForeName>Jordan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Medicine, Deakin University, Geelong, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Alfred Health, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infection and Immunity, Murdoch Children's Research Institute, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toh</LastName><ForeName>Zheng Quan</ForeName><Initials>ZQ</Initials><AffiliationInfo><Affiliation>Infection and Immunity, Murdoch Children's Research Institute, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics, The University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Do</LastName><ForeName>Lien Anh Ha</ForeName><Initials>LAH</Initials><AffiliationInfo><Affiliation>Infection and Immunity, Murdoch Children's Research Institute, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics, The University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mulholland</LastName><ForeName>Kim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Infection and Immunity, Murdoch Children's Research Institute, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics, The University of Melbourne, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Licciardi</LastName><ForeName>Paul V</ForeName><Initials>PV</Initials><AffiliationInfo><Affiliation>Infection and Immunity, Murdoch Children's Research Institute, Melbourne, VIC, Australia. paul.licciardi@mcri.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatrics, The University of Melbourne, Melbourne, VIC, Australia. paul.licciardi@mcri.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pediatr Res</MedlineTA><NlmUniqueID>0100714</NlmUniqueID><ISSNLinking>0031-3998</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000705967">pediatric multisystem inflammatory disease, COVID-19 related</SupplMeshName><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>15</Day><Hour>23</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35970935</ArticleId><ArticleId IdType="pmc">PMC9376896</ArticleId><ArticleId IdType="doi">10.1038/s41390-022-02254-x</ArticleId><ArticleId IdType="pii">10.1038/s41390-022-02254-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization (WHO). WHO Coronavirus (COVID-19) &#x2013; Global Situation (accessed 30 March 2022); https://covid19.who.int/ (2021).</Citation></Reference><Reference><Citation>Park, Y. J. et al. Contact tracing during Coronavirus Disease outbreak, South Korea, 2020. Emerg. Infect. Dis.26, 2465&#x2013;2468 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7510731</ArticleId><ArticleId IdType="pubmed">32673193</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO). Transmission of SARS-CoV-2: Implications for Infection Prevention Precautions (accessed 30 March 2022); https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions (2020).</Citation></Reference><Reference><Citation>Chan JF, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:514&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159286</ArticleId><ArticleId IdType="pubmed">31986261</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf6;tzinger F, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc. Health. 2020;4:653&#x2013;661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7316447</ArticleId><ArticleId IdType="pubmed">32593339</ArticleId></ArticleIdList></Reference><Reference><Citation>Bialek S, et al. Coronavirus disease 2019 in children &#x2014; United States, February 12&#x2013;April 2, 2020. MMWR Morb. Mortal. Wkly Rep. 2020;69:422&#x2013;426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7147903</ArticleId><ArticleId IdType="pubmed">32271728</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong, Y. et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics145, e20200702 (2020).</Citation></Reference><Reference><Citation>Swann OV, et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. BMJ. 2020;370:m3249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7488201</ArticleId><ArticleId IdType="pubmed">32960186</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020;109:1088&#x2013;1095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228328</ArticleId><ArticleId IdType="pubmed">32202343</ArticleId></ArticleIdList></Reference><Reference><Citation>SAGE Working Group. WHO SAGE Roadmap for Prioritizing Uses of COVID-19 Vaccines in the Context of Limited Supply (World Health Organisation (WHO), 2020).</Citation></Reference><Reference><Citation>World Health Organisation (WHO). Tracking SARS-CoV-2 Variants (accessed 16 April 2022); https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ (2022).</Citation></Reference><Reference><Citation>Riley, S. et al. REACT-1 round 12 report: resurgence of SARS-CoV-2 infections in England associated with increased frequency of the Delta variant. Preprint at medRxiv 2021.06.17.21259103 (2021).</Citation></Reference><Reference><Citation>Centre for Disease Control and Prevention (CDC). Delta Variant: What We Know About The Science (accessed 22 October 2021); https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html (2021).</Citation></Reference><Reference><Citation>Marks KJ, et al. Hospitalization of infants and children aged 0&#x2013;4 years with laboratory-confirmed COVID-19 &#x2014; COVID-NET, 14 states, March 2020&#x2013;February 2022. MMWR Morb. Mortal. Wkly Rep. 2022;71:429&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8942304</ArticleId><ArticleId IdType="pubmed">35298458</ArticleId></ArticleIdList></Reference><Reference><Citation>Cloete J, et al. Paediatric hospitalisations due to COVID-19 during the first SARS-CoV-2 omicron (B.1.1.529) variant wave in South Africa: a multicentre observational study. Lancet Child Adolesc. Health. 2022;6:294&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8856663</ArticleId><ArticleId IdType="pubmed">35189083</ArticleId></ArticleIdList></Reference><Reference><Citation>Preston LE, et al. Characteristics and disease severity of US children and adolescents diagnosed with COVID-19. JAMA Netw. Open. 2021;4:e215298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8035649</ArticleId><ArticleId IdType="pubmed">33835179</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel DA, et al. Trends in COVID-19 cases, emergency department visits, and hospital admissions among children and adolescents aged 0-17 years &#x2013; United States, August 2020-August 2021. MMWR Morb. Mortal. Wkly Rep. 2021;70:1249&#x2013;1254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8437056</ArticleId><ArticleId IdType="pubmed">34499628</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitano T, et al. The differential impact of pediatric COVID-19 between high-income countries and low- and middle-income countries: a systematic review of fatality and ICU admission in children worldwide. PLoS ONE. 2021;16:e0246326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7845974</ArticleId><ArticleId IdType="pubmed">33513204</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO). Who COVID-19 Dashboard &#x2013; Cases and Deaths with Age and Sex Reported (World Health Organization (WHO), Geneva, 2022).</Citation></Reference><Reference><Citation>Viner RM, et al. School closure and management practices during coronavirus outbreaks including COVID-19: a rapid systematic review. Lancet Child Adolesc. Health. 2020;4:397&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270629</ArticleId><ArticleId IdType="pubmed">32272089</ArticleId></ArticleIdList></Reference><Reference><Citation>GISAID and Nextstrain. Genomic Epidemiology of Novel Coronavirus &#x2013; Global Subsampling (accessed 16 April 2022); https://nextstrain.org/ncov/gisaid/global (2022).</Citation></Reference><Reference><Citation>Fisman, D. N. &amp; Tuite, A. R. Progressive increase in virulence of novel SARS-CoV-2 variants in Ontario, Canada. CMAJ193, E1619&#x2013;E1625 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8562985</ArticleId><ArticleId IdType="pubmed">34610919</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397:2461&#x2013;2462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8201647</ArticleId><ArticleId IdType="pubmed">34139198</ArticleId></ArticleIdList></Reference><Reference><Citation>Delahoy, M. J., Ujamaa, D. &amp; Whitaker, M. Hospitalizations associated with COVID-19 among children and adolescents&#x2014;COVID-NET, 14 states, March 1, 2020&#x2013;August 14, 2021. MMWR Morb. Mortal. Wkly Rep.70, 1255&#x2013;1260 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8437052</ArticleId><ArticleId IdType="pubmed">34499627</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin, B. et al. Acute upper airway disease in children with the Omicron (B.1.1.529) variant of SARS-CoV-2&#x2014;a report from the US National COVID Cohort Collaborative. JAMA Pediatr.176, 819&#x2013;821 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9012983</ArticleId><ArticleId IdType="pubmed">35426941</ArticleId></ArticleIdList></Reference><Reference><Citation>Butt, A. A. et al. COVID-19 disease severity in children infected with the Omicron variant. Clin. Infect. Dis. ciac275 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047187</ArticleId><ArticleId IdType="pubmed">35404391</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, L. et al. Incidence rates and clinical outcomes of SARS-CoV-2 infection with the Omicron and Delta variants in children younger than 5 years in the US. JAMA Pediatr.176, 811&#x2013;813 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8976262</ArticleId><ArticleId IdType="pubmed">35363246</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein NP, et al. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 years - VISION Network, 10 states, April 2021-January 2022. MMWR Morb. Mortal. Wkly. Rep. 2022;71:352&#x2013;358.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893336</ArticleId><ArticleId IdType="pubmed">35239634</ArticleId></ArticleIdList></Reference><Reference><Citation>Price, A. M. et al. BNT162b2 protection against the Omicron variant in children and adolescents. N. Engl. J. Med.386, 1899&#x2013;1909 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9006785</ArticleId><ArticleId IdType="pubmed">35353976</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat. Med. 2020;26:502&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095102</ArticleId><ArticleId IdType="pubmed">32284613</ArticleId></ArticleIdList></Reference><Reference><Citation>Han MS, et al. Viral RNA load in mildly symptomatic and asymptomatic children with COVID-19, Seoul, South Korea. Emerg. Infect. Dis. 2020;26:2497&#x2013;2499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7510743</ArticleId><ArticleId IdType="pubmed">32497001</ArticleId></ArticleIdList></Reference><Reference><Citation>Madewell ZJ, Yang Y, Longini IM, Jr, Halloran ME, Dean NE. Household transmission of SARS-CoV-2: a systematic review and meta-analysis. JAMA Netw. Open. 2020;3:e2031756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737089</ArticleId><ArticleId IdType="pubmed">33315116</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg ES, et al. COVID-19 testing, epidemic features, hospital outcomes, and household prevalence, New York State&#x2014;March 2020. Clin. Infect. Dis. 2020;71:1953&#x2013;1959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7239264</ArticleId><ArticleId IdType="pubmed">32382743</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung E, et al. Comparison of symptoms and RNA levels in children and adults with SARS-CoV-2 infection in the community setting. JAMA Pediatr. 2021;175:e212025.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8491103</ArticleId><ArticleId IdType="pubmed">34115094</ArticleId></ArticleIdList></Reference><Reference><Citation>Parri N, Lenge M, Buonsenso D. Children with COVID-19 in pediatric emergency departments in Italy. N. Engl. J. Med. 2020;383:187&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7206930</ArticleId><ArticleId IdType="pubmed">32356945</ArticleId></ArticleIdList></Reference><Reference><Citation>Haapanen, M., Renko, M., Artama, M. &amp; Kuitunen, I. The impact of the lockdown and the re-opening of schools and day cares on the epidemiology of SARS-CoV-2 and other respiratory infections in children &#x2013; a nationwide register study in Finland. EClinicalMedicine34, 100807 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8007090</ArticleId><ArticleId IdType="pubmed">33817612</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell, F. et al. COVID-19 in Victorian Schools: an Analysis of Child-care and School Outbreak Data and Evidence-based Recommendations for Opening Schools and Keeping Them Open (Murdoch Children&#x2019;s Research Institute and the University of Melbourne, Melbourne, Australia, 2020).</Citation></Reference><Reference><Citation>Murdoch Children&#x2019;s Research Institute. COVID-19 and Children&#x2019;s Surveillance Report: Number 13, Compiled: 21 March 2022 (MCRI, Melbourne, 2022).</Citation></Reference><Reference><Citation>Macartney K, et al. Transmission of SARS-CoV-2 in Australian educational settings: a prospective cohort study. Lancet Child Adolesc. Health. 2020;4:807&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7398658</ArticleId><ArticleId IdType="pubmed">32758454</ArticleId></ArticleIdList></Reference><Reference><Citation>Gettings, J. R. et al. Severe Acute Respiratory Syndrome Coronavirus 2 transmission in a Georgia School District&#x2014;United States, December 2020&#x2013;January 2021. Clin. Infect. Dis.74, 319&#x2013;326 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8083290</ArticleId><ArticleId IdType="pubmed">33864375</ArticleId></ArticleIdList></Reference><Reference><Citation>National Centre of Immunisation Research and Surveillance (NCIRS). COVID-19 in Schools and Early Childhood Education and Care Services &#x2013; The Experience in NSW: 16 June to 31 July 2021 (NSW Government, Canberra, 2021).</Citation></Reference><Reference><Citation>National Centre of Immunisation Research and Surveillance (NCIRS). COVID-19 in Schools &#x2013; The Experience in NSW: 18 October 2021 to 17 December 2021 (NSW, 2022).</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Control (ECDC). COVID-19 in Children and the Role of School Settings in Transmission &#x2013; Second Update (ECDC, Stockholm, 2021).</Citation></Reference><Reference><Citation>Australian Department of Health. Coronavirus (COVID-19) at a Glance Infographic Collection: April 2020&#x2013;April 2022 (Australian Department of Health, 2021).</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC). Demographic Trends of COVID-19 Cases and Deaths in the US Reported to CDC (U.S. Department of Health &amp; Human Services, 2022).</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Control (ECDC). COVID-19 Surveillance Report: Week 43, 2022 &#x2013; Age-sex Distribution of Cases at Different Levels of Severity and by Time Period, Pooled Data for EU/EEA Countries (ECDC, Stockholm, 2022).</Citation></Reference><Reference><Citation>Public Health England. Coronavirus (COVID) in the UK: Age Demographic of Cases by Specimen Date (GOV.UK, 2022).</Citation></Reference><Reference><Citation>Tsankov BK, et al. Severe COVID-19 infection and pediatric comorbidities: a systematic review and meta-analysis. Int J. Infect. Dis. 2021;103:246&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7679116</ArticleId><ArticleId IdType="pubmed">33227520</ArticleId></ArticleIdList></Reference><Reference><Citation>UNICEF. UNICEF Indonesia COVID-19 Response Situation Reports: May 2020 (accessed 16 April 2022); https://reliefweb.int/report/indonesia/unicef-indonesia-covid-19-response-situation-report-may-7-2020 (2020).</Citation></Reference><Reference><Citation>Payne AB, et al. Incidence of multisystem inflammatory syndrome in children among US persons infected with SARS-CoV-2. JAMA Netw. Open. 2021;4:e2116420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8193431</ArticleId><ArticleId IdType="pubmed">34110391</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrams JY, et al. Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study. Lancet Child Adolesc. Health. 2021;5:323&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7943393</ArticleId><ArticleId IdType="pubmed">33711293</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organisation (WHO). Living Guidance for Clinical Management of COVID-19: Living Guidance, 23 November 2021 (WHO, Geneva, 2021).</Citation></Reference><Reference><Citation>Dionne A, Son MBF, Randolph AG. An update on multisystem inflammatory syndrome in children related to SARS-CoV-2. Pediatr. Infect. Dis. J. 2022;41:e6&#x2013;e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8658063</ArticleId><ArticleId IdType="pubmed">34889873</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC). Health Department-reported Cases of Multisystem Inflammatory Syndrome in Children (MIS-C) in the United States (accessed 16 April 2022); https://covid.cdc.gov/covid-data-tracker/#mis-national-surveillance (2021).</Citation></Reference><Reference><Citation>Radia T, et al. Multi-system inflammatory syndrome in children &amp; adolescents (MIS-C): a systematic review of clinical features and presentation. Paediatr. Respir. Rev. 2021;38:51&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7417920</ArticleId><ArticleId IdType="pubmed">32891582</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonsenso D, et al. Preliminary evidence on long COVID in children. Acta Paediatr. 2021;110:2208&#x2013;2211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8251440</ArticleId><ArticleId IdType="pubmed">33835507</ArticleId></ArticleIdList></Reference><Reference><Citation>Munblit, D., Sigfrid, L. &amp; Warner, J. O. Setting priorities to address research gaps in long-term COVID-19 outcomes in children. JAMA Pediatr.175, 1095&#x2013;1096 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34338711</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann, P., Pittet, L. F. &amp; Curtis, N. How common is long COVID in children and adolescents? Pediatr. Infect. Dis. J.40, e482&#x2013;e487 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8575095</ArticleId><ArticleId IdType="pubmed">34870392</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin-Chowdhury Z, Ladhani SN. Causation or confounding: why controls are critical for characterizing long COVID. Nat. Med. 2021;27:1129&#x2013;1130.</Citation><ArticleIdList><ArticleId IdType="pubmed">34140704</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. Technical Article: Updated Estimates of the Prevalence of Post-acute Symptoms among People with Coronavirus (COVID-19) in the UK: 26 April 2020 to 1 August 2021 (UK Government, London, 2021).</Citation></Reference><Reference><Citation>Zimmermann, P., Pittet, L. F. &amp; Curtis, N. The challenge of studying long COVID: an updated review. Pediatr. Infect. Dis. J.41, 424&#x2013;426 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8997013</ArticleId><ArticleId IdType="pubmed">35213866</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodin, P. et al. Studying severe long COVID to understand post-infectious disorders beyond COVID-19. Nat. Med.28, 879&#x2013;882 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35383311</ArticleId></ArticleIdList></Reference><Reference><Citation>Mali AS, Magdum M, Novotny J. COVID-19 impact on reproduction and fertility. JBRA Assist Reprod. 2021;25:310&#x2013;313.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8083847</ArticleId><ArticleId IdType="pubmed">33507714</ArticleId></ArticleIdList></Reference><Reference><Citation>Neeland MR, et al. Innate cell profiles during the acute and convalescent phase of SARS-CoV-2 infection in children. Nat. Commun. 2021;12:1084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7889848</ArticleId><ArticleId IdType="pubmed">33597531</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierce, C. A. et al. Natural mucosal barriers and COVID-19 in children. JCI Insight6, e148694 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262299</ArticleId><ArticleId IdType="pubmed">33822777</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosif S, et al. Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19. Nat. Commun. 2020;11:5703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7658256</ArticleId><ArticleId IdType="pubmed">33177504</ArticleId></ArticleIdList></Reference><Reference><Citation>Rydyznski Moderbacher C, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183:996&#x2013;1012.e19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7494270</ArticleId><ArticleId IdType="pubmed">33010815</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeyanathan M, et al. Immunological considerations for COVID-19 vaccine strategies. Nat. Rev. Immunol. 2020;20:615&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7472682</ArticleId><ArticleId IdType="pubmed">32887954</ArticleId></ArticleIdList></Reference><Reference><Citation>Kannan S, Shaik Syed Ali P, Sheeza A. Omicron (B.1.1.529) &#x2013; variant of concern &#x2013; molecular profile and epidemiology: a mini review. Eur. Rev. Med Pharm. Sci. 2021;25:8019&#x2013;8022.</Citation><ArticleIdList><ArticleId IdType="pubmed">34982466</ArticleId></ArticleIdList></Reference><Reference><Citation>Murchu EO, et al. Immune response following infection with SARS-CoV-2 and other coronaviruses: a rapid review. Rev. Med. Virol. 2021;31:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7536965</ArticleId><ArticleId IdType="pubmed">32964627</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Y. et al. Differential antibody dynamics to SARS-CoV-2 infection and vaccination. Preprint at bioRxiv 2021.09.09.459504 (2021).</Citation></Reference><Reference><Citation>Vitale J, et al. Assessment of SARS-CoV-2 reinfection 1 year after primary infection in a population in Lombardy, Italy. JAMA Intern. Med. 2021;181:1407&#x2013;1408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8164145</ArticleId><ArticleId IdType="pubmed">34048531</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H, Bertollini R, Abu-Raddad LJ. Efficacy of natural immunity against SARS-CoV-2 reinfection with the Beta variant. N. Engl. J. Med. 2021;385:2585&#x2013;2586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8693689</ArticleId><ArticleId IdType="pubmed">34910864</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang AT, et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat. Commun. 2020;11:4704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499300</ArticleId><ArticleId IdType="pubmed">32943637</ArticleId></ArticleIdList></Reference><Reference><Citation>Selva KJ, et al. Systems serology detects functionally distinct coronavirus antibody features in children and elderly. Nat. Commun. 2021;12:2037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8016934</ArticleId><ArticleId IdType="pubmed">33795692</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenck RW, et al. Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents. N. Engl. J. Med. 2021;385:239&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8174030</ArticleId><ArticleId IdType="pubmed">34043894</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali, K. et al. Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents. N. Engl. J. Med.385, 2241&#x2013;2251 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8385554</ArticleId><ArticleId IdType="pubmed">34379915</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter EB, et al. Evaluation of the BNT162b2 COVID-19 vaccine in children 5 to 11 years of age. N. Engl. J. Med. 2021;386:35&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8609605</ArticleId><ArticleId IdType="pubmed">34752019</ArticleId></ArticleIdList></Reference><Reference><Citation>Moderna Inc. Moderna Accounces its COVID-19 Vaccine Phase 2/3 Study in Children 6 Months to under 6 Years has Successfully Met its Primary Endpoint (accessed 20 April 2022); https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-its-COVID-19-Vaccine-Phase-23-Study-in-Children-6-Months-to-Under-6-Years-Has-Successfully-Met-Its-Primary-Endpoint/default.aspx (2022).</Citation></Reference><Reference><Citation>Thompson MG, et al. Prevention and attenuation of COVID-19 with the BNT162b2 and mRNA-1273 vaccines. N. Engl. J. Med. 2021;385:320&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262622</ArticleId><ArticleId IdType="pubmed">34192428</ArticleId></ArticleIdList></Reference><Reference><Citation>Han, B. et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. Lancet Infect. Dis.21, 1645&#x2013;1653 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8238449</ArticleId><ArticleId IdType="pubmed">34197764</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia, S. et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. Lancet Infect. Dis.22, 196&#x2013;208 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8443232</ArticleId><ArticleId IdType="pubmed">34536349</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organisation (WHO). The Sinovac-CoronaVac COVID-19 Vaccine: What You Need to Know &#x2013; Updated 2 September 2021 (accessed 16 April 2022); https://www.who.int/news-room/feature-stories/detail/the-sinovac-covid-19-vaccine-what-you-need-to-know (2021).</Citation></Reference><Reference><Citation>World Health Organisation (WHO). The Sinopharm COVID-19 Vaccine: What You Need to Know &#x2013; Updated 2 September 2021 (accessed 26 October 2021); https://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know (2021).</Citation></Reference><Reference><Citation>National Center for Medical Sciences Information. Press Release 29 September 2021: How is Immunization against COVID-19 Working in Cuba? (accessed 25 October 2021); https://actualidad.sld.cu/ (2021).</Citation></Reference><Reference><Citation>Puga-G&#xf3;mez, R. et al. Open label phase I/II clinical trial and predicted efficacy of SARS-CoV-2 RBD protein vaccines SOBERANA 02 and SOBERANA Plus in children. Preprint at medRxiv 2022.03.03.22271313 (2022).</Citation></Reference><Reference><Citation>Ministry of Science &amp; Technology (India). DBT-BIRAC Supported ZyCoV-D Developed by Zydus Cadila Receives Emergency Use Authorization: 20 August 2021 (accessed 20 April 2022); https://www.pib.gov.in/PressReleasePage.aspx?PRID=1747669 (2021).</Citation></Reference><Reference><Citation>Khobragade A, et al. Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. Lancet. 2022;399:1313&#x2013;1321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8970574</ArticleId><ArticleId IdType="pubmed">35367003</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health and Family Welfare (India). Children Vaccination (accessed 12 April 2022); https://www.cowin.gov.in/ (2022).</Citation></Reference><Reference><Citation>The World Health Organisation (WHO). The Bharat Biotech BBV152 COVAXIN Vaccine against COVID-19: What You Need to Know (accessed 20 April 2022); https://www.who.int/news-room/feature-stories/detail/the-bharat-biotech-bbv152-covaxin-vaccine-against-covid-19-what-you-need-to-know (2022).</Citation></Reference><Reference><Citation>Figueroa JP, et al. Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics. Lancet. 2021;397:562&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7906712</ArticleId><ArticleId IdType="pubmed">33516284</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub RL, Subramanian L, Karlage A, Ahmad I, Rosenberg J. COVID-19 vaccine to vaccination: why leaders must invest in delivery strategies now. Health Aff. (Millwood) 2021;40:33&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">33211554</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy M, et al. Multisystem inflammatory syndrome in children by COVID-19 vaccination status of adolescents in France. JAMA. 2022;327:281&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8689418</ArticleId><ArticleId IdType="pubmed">34928295</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health (Chile). COVID-19: More than 80% of Children between 3 and 17 Years Old Have Completed their Vaccination Schedule: 8 March 2022 (accessed 12 April 2022); https://www.minsal.cl/covid-19-mas-del-80-de-los-ninos-entre-3-y-17-anos-ha-completado-su-esquema-de-vacunacion/ (2022).</Citation></Reference><Reference><Citation>UNESCO. COVID-19 Impact on Education (accessed 31 August 2021); https://en.unesco.org/covid19/educationresponse#schoolclosures (2021).</Citation></Reference><Reference><Citation>Commision for Children and Young People. Impact of COVID-19 on Children and Young People: Mental Health (CCYP, Victoria, 2020).</Citation></Reference><Reference><Citation>The Royal Children&#x2019;s Hospital National Child Health Poll. Poll 18 &#x2013; COVID-19 Pandemic: Effects on the Lives of Australian Children and Families (accessed 16 April 2022); https://www.rchpoll.org.au/wp-content/uploads/2020/07/nchp-poll18-report-covid.pdf (2020).</Citation></Reference><Reference><Citation>The Royal Children&#x2019;s Hospital National Child Health Poll. Routine Childhood Vaccinations: Effects of the COVID-19 Pandemic. Poll Number 18 Supplementary Report (accessed 31 August 2021); https://www.rchpoll.org.au/wp-content/uploads/2020/08/nchp-immunisation-embargoed.pdf (2020).</Citation></Reference><Reference><Citation>Causey K, et al. Estimating global and regional disruptions to routine childhood vaccine coverage during the COVID-19 pandemic in 2020: a modelling study. Lancet. 2021;398:522&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8285122</ArticleId><ArticleId IdType="pubmed">34273292</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Canada. Health Canada Updates Pfizer-BioNTech and Moderna COVID-19 Vaccine Labels to Include Information on Myocarditis and Pericarditis (accessed 31 August 2021); https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2021/75959a-eng.php (2021).</Citation></Reference><Reference><Citation>Vaccine Safety Team CDC COVID-19 Vaccine Task Force. COVID-19 Vaccine Safety Updates from Vaccines and Related Biological Products Advisory Committee (VRBPAC): 10 June 2021 (accessed 31 July 2021); https://www.fda.gov/media/150054/download (2021).</Citation></Reference><Reference><Citation>Pharmacovigilance Risk Assessment Commitee (PRAC). Safety News Update: Comirnaty and Spikevax: Possible Link to Very Rare Cases of Myocarditis and Pericarditis: 9 July 2021 (accessed 21 October 2021); https://www.ema.europa.eu/en/news/comirnaty-spikevax-possible-link-very-rare-cases-myocarditis-pericarditis (2021).</Citation></Reference><Reference><Citation>Public Health Agency (Sweden). Moderna&#x2019;s COVID-19 Vaccine Spikevax Halted for Young People (accessed 11 October 2021); https://www.krisinformation.se/en/news/2021/october/moderna-vaccine-spikevax-halted-for-young-people (2021).</Citation></Reference><Reference><Citation>Norwegian Institute of Public Health (NIPH). Myocarditis in Boys and Young Men Can Occur More Often after the Spikevax Vaccine from Moderna (accessed 11 October 2021); https://www.fhi.no/en/news/2021/myocarditis-in-boys-and-young-men-can-occur-more-often-after-the-spikevax-v/ (2021).</Citation></Reference><Reference><Citation>Advisory Committee on Immunization Practices (ACIP). Myocarditis Analyses in the Vaccine Safety Datalink: Rapid Cycle Analyses and &#x201c;Head-to-Head&#x201d; Product Comparisons. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-10-20-21/08-COVID-Klein-508.pdf (2021).</Citation></Reference><Reference><Citation>Hause AM, et al. COVID-19 vaccine safety in children aged 5&#x2013;11 years&#x2014;United States, November 3&#x2013;December 19, 2021. MMWR Morb. Mortal. Wkly Rep. 2021;70:1755&#x2013;1760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8736274</ArticleId><ArticleId IdType="pubmed">34968370</ArticleId></ArticleIdList></Reference><Reference><Citation>Barda N, et al. Safety of the BNT162b2 mRNA COVID-19 vaccine in a nationwide setting. N. Engl. J. Med. 2021;385:1078&#x2013;1090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8427535</ArticleId><ArticleId IdType="pubmed">34432976</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehmer TK, et al. Association between COVID-19 and myocarditis using hospital-based administrative data&#x2014;United States, March 2020&#x2013;January 2021. MMWR Morb. Mortal. Wkly Rep. 2021;70:1228&#x2013;1232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8422872</ArticleId><ArticleId IdType="pubmed">34473684</ArticleId></ArticleIdList></Reference><Reference><Citation>AstraZeneca and University of Oxford. Oxford/AstraZeneca COVID-19 Vaccine Effectiveness in England (RAVEN): NCT05047822 (accessed 27 October 2021); https://clinicaltrials.gov/ct2/show/NCT05047822?term=oxford&amp;cond=COVID-19&amp;age=0&amp;draw=2&amp;rank=1 (2021).</Citation></Reference><Reference><Citation>Buntsma, D., Cheng, D., Machingaifa, F. &amp; McGuire, R. COVID-19 Vaccination in Children: Immunisation References (accessed 20 April 2022); https://mvec.mcri.edu.au/immunisation-references/#n (2022).</Citation></Reference><Reference><Citation>Population Pyramid. National Population by Sex and Age (accessed 31 August 2021); https://www.populationpyramid.net/sources (2021).</Citation></Reference><Reference><Citation>Reuters. Factbox: Countries Vaccinating Children against COVID-19: 2 December 2021 (accessed 17 April 2022); https://www.reuters.com/business/healthcare-pharmaceuticals/countries-vaccinating-children-against-covid-19-2021-06-29/ (2021).</Citation></Reference><Reference><Citation>Department of Health (Republic of South Africa). Vaccine Information Portal (accessed 17 April 2022); https://sacoronavirus.co.za/vaccine-updates/ (2022).</Citation></Reference><Reference><Citation>Ministry of Health and Child Care (Zimbabwe). Teenagers now Eligible for Vaccination: 1 September 2021 (accessed 17 April 2022); http://www.mohcc.gov.zw/index.php?option=com_content&amp;view=article&amp;id=403:teenagers-now-eligible-for-vaccination&amp;catid=84&amp;Itemid=435 (2021).</Citation></Reference><Reference><Citation>Reuters. Venezuela Begins Vaccinating 2-Year-Old Children with Cuban Doses&#x2014;Vice President (accessed 17 April 2022); https://www.reuters.com/business/healthcare-pharmaceuticals/venezuela-begins-vaccinating-2-year-old-children-with-cuban-doses-vice-president-2021-11-08/ (2021).</Citation></Reference><Reference><Citation>U.S Food &amp; Drug Administration. Comirnaty and Pfizer-BioNTech COVID-19 Vaccine: Updated 29 March 2022 (accessed 12 April 2022); https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine (2022).</Citation></Reference><Reference><Citation>Ministry of Public Health (Uruguay). Technical Report: Vaccination against COVID-19 in the Pediatric Population Aged 5 to 11 Years: 29 November 2021 (accessed 12th Apr 2022); https://www.gub.uy/ministerio-salud-publica/comunicacion/publicaciones/informe-tecnico-vacunacion-contra-covid-19-poblacion-pediatrica-5-11 (2021).</Citation></Reference><Reference><Citation>Agencia Brasil. Institute Requestes Recommendation to Vaccinate Children Aged 3 to 5: Published 14 March 2022 (accessed 12 April 2022); https://agenciabrasil.ebc.com.br/en/saude/noticia/2022-03/institute-requestes-recommendation-vaccinate-children-aged-3-5 (2022).</Citation></Reference><Reference><Citation>Public Health Agency (Canada). Vaccines for Children: COVID-19: Updated 17 March 2022 (accessed 12 April 2022); https://www.canada.ca/en/public-health/services/vaccination-children/covid-19.html (2022).</Citation></Reference><Reference><Citation>Department of Health (Columbia). COVID-19 Vaccines for Children 5 to 11 (accessed 17 April 2022); https://www2.gov.bc.ca/gov/content/covid-19/vaccine/children (2022).</Citation></Reference><Reference><Citation>Ministry of Health (Argentina). What Vaccines Are We Applying in the Country? Updated 21 September 2021 (accessed 12 April 2022); https://www.argentina.gob.ar/coronavirus/vacuna/cuales (2021).</Citation></Reference><Reference><Citation>Secretariat of Health (Mexico). Summary of the Main Characteristics of the Vaccines Available in Mexico (accessed 12 April 2022); http://vacunacovid.gob.mx/wordpress/informacion-de-la-vacuna/ (2022).</Citation></Reference><Reference><Citation>National Medical Products Administration. Vaccination of Young Children Begins around Country: Updated 26 October 2021 (accessed 12 April 2022); http://subsites.chinadaily.com.cn/nmpa/2021-10/26/c_671254.htm (2021).</Citation></Reference><Reference><Citation>Reuters. Cambodia Vaccinates Children Aged Three to Five against COVID (accessed 17 April 2022); https://www.reuters.com/business/healthcare-pharmaceuticals/cambodia-vaccinates-children-aged-three-five-against-covid-2022-02-23/ (2022).</Citation></Reference><Reference><Citation>Therapeutic Goods Administration (TGA). COVID-19 Vaccine: Provisional Registrations (accessed 12 April 2022); https://www.tga.gov.au/covid-19-vaccine-provisional-registrations (2022).</Citation></Reference><Reference><Citation>Ministry of Health Labour and Welfare (Japan). The Vaccination: Available COVID-19 Vaccines (accessed 12 April 2022); https://v-sys.mhlw.go.jp/en/about/ (2022).</Citation></Reference><Reference><Citation>Ministry of Health (Malaysia). PICkids COVID Vaccination Program: Children Aged 5 to under 12 (accessed 12 April 2022); https://covid-19.moh.gov.my/vaksin-covid-19/pickids (2022).</Citation></Reference><Reference><Citation>Ministry of Health (Singapore). COVID-19 Vaccinating Your Child: Who is Eligble? (accessed 12 April 2022); https://www.moh.gov.sg/covid-19/vaccination/faqs---children-related-vaccination-matters (2022).</Citation></Reference><Reference><Citation>Smith, J. S. Korea Approves Pfizer COVID-19 Vaccine for Children Aged 5-11 (Reuters, 2022).</Citation></Reference><Reference><Citation>MedSafe New Zealand Medicines and Medical Devices Safety Authority. Approval Status of COVID Vaccines Applications Received by Medsafe: 20 March 2022 (accessed 12 April 2022); https://www.medsafe.govt.nz/COVID-19/status-of-applications.asp (2021).</Citation></Reference><Reference><Citation>Food and Drug Administration Ministry of Public Health (Thailand). FDA Press Release: FDA Approves Pfizer in Children 5 to 11 years: 20 December 2021 (accessed 12 April 2022); https://www.fda.moph.go.th/SitePages/News.aspx?IDitem=1427 (2021).</Citation></Reference><Reference><Citation>Food and Drug Administration Ministry of Public Health (Thailand). FDA Press Release: FDA Approves Sinovac and Sinopharm for Use in Children 6 and Older: 4 February 2022. https://www.fda.moph.go.th/SitePages/News.aspx?IDitem=1457 (2022).</Citation></Reference><Reference><Citation>Ministry of Health (Indonesia). The Government Holds a Kick off for COVID-19 Vaccinations for Children Age 6-11 Years Simultaneously in 3 Provinces: 14 December 2021 (accessed 16 April 2022); https://www.kemkes.go.id/article/view/21121400001/pemerintah-gelar-kick-off-vaksinasi-covid-19-anak-usia-6-11-tahun-serentak-di-3-provinsi.html (2021).</Citation></Reference><Reference><Citation>Baljma, T. Children Aged 12-15 to be Offered COVID-19 Vaccine: 23 July 2021 (accessed 12 April 2022); https://montsame.mn/en/read/268007 (2021).</Citation></Reference><Reference><Citation>European Medicines Agency. COVID-19 Vaccines: Authorised (accessed 12 April 2022); https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised (2022).</Citation></Reference><Reference><Citation>Public Health England. A Guide for Parents of Children Aged 5 to 11 Years: updated 28 March 2022 (accessed 12 April 2022); https://www.gov.uk/government/publications/covid-19-vaccination-resources-for-children-aged-5-to-11-years/a-guide-for-parents-of-children-aged-5-to-11-years (2021).</Citation></Reference><Reference><Citation>Federal Office of Public Health (FOPH). Coronavirus: Vaccination. Updated 31 March 2022 (accessed 12 April 2022); https://www.bag.admin.ch/bag/en/home/krankheiten/ausbrueche-epidemien-pandemien/aktuelle-ausbrueche-epidemien/novel-cov/impfen.html (2022).</Citation></Reference><Reference><Citation>Ministry of Health (Netherlands). Coronavirus Vaccination for Children Aged 5 to 11 (accessed 17 April 2022); https://www.government.nl/topics/coronavirus-covid-19/dutch-vaccination-programme/vaccination-of-children-aged-5-to-11 (2022).</Citation></Reference><Reference><Citation>Finish Institue for Health and Welfare. Coronavirus Vaccinations for Children and Young People (accessed 17 April 2022); https://thl.fi/en/web/infectious-diseases-and-vaccinations/what-s-new/coronavirus-covid-19-latest-updates/vaccines-and-coronavirus/coronavirus-vaccinations-for-children-and-young-people#:~:text=Coronavirus%20vaccinations%20are%20currently%20offered,be%20vaccinated%20from%20now%20on (2022).</Citation></Reference><Reference><Citation>Public Health Agency of (Sweden). Children and Adolescents &#x2013; Vaccination against COVID-19 (accessed 17 April 2022); https://www.folkhalsomyndigheten.se/the-public-health-agency-of-sweden/communicable-disease-control/covid-19/vaccination-against-covid-19/children-and-adolescents--information-about-vaccination-against-covid-19/ (2021).</Citation></Reference><Reference><Citation>Russian News Agency. Russia Approves COVID-19 Vaccine for Teenagers, Developer Says (accessed 17 April 2022); https://tass.com/society/1365751 (2021).</Citation></Reference><Reference><Citation>Ministry of Health (Germany). Vaccines against COVID-19: Comirnaty&#xae; by BioNTech/Pfizer: 14 October 2021 (accessed 17 April 2022); https://www.zusammengegencorona.de/en/vaccines-against-covid-19-comirnaty-r-by-biontech-pfizer/ (2021).</Citation></Reference><Reference><Citation>Ministry of Health (Israel). COVID-19 Vaccine for Children (accessed 12 April 2022); https://corona.health.gov.il/en/vaccine-for-covid/under-12/ (2021).</Citation></Reference><Reference><Citation>Mehdi, S. Z. Iran Approves Vaccination of Children Aged 5-11: 22 January 2022 (Anadolu Agency, 2022).</Citation></Reference><Reference><Citation>Ministry of National Health Services Regulation &amp; Cordination (Pakistan). Pfizer COVID Vaccine Guidelines: 19 November 2021 (accessed 12 April 2022); https://storage.covid.gov.pk/new_guidelines/19November2021_20211119_Interim_Guidelines_for_Pfizer_Vaccine_for_COVID_19_7307_(1).pdf (2021).</Citation></Reference><Reference><Citation>Ministry of Health (Saudi Arabia). COVID-19 &amp; Vaccine FAQs (accessed 12 April 2022); https://www.moh.gov.sa/en/Ministry/HotTopics/Pages/COVID-19-Vaccine.aspx (2022).</Citation></Reference><Reference><Citation>Ministry of Health (UAE). Vaccines against COVID-10 in the UAE. https://u.ae/en/information-and-services/justice-safety-and-the-law/handling-the-covid-19-outbreak/vaccines-against-covid-19-in-the-uae (2022).</Citation></Reference><Reference><Citation>Ministry of Health (Ukraine). The Ministry of Health Recommends in Some Cases to Vaccinate Children 12+ against COVID-19: 30 July 2021 (accessed 12 April 2022); https://vaccination.covid19.gov.ua/news/childrenvaccination (2021).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>